Outlook Therapeutics, Inc. (OTLK)
Health Care · Ophthalmic Biologics / Retinal Therapeutics · NASDAQ
Outlook Therapeutics develops ophthalmic biologics for retinal diseases, with its lead product LYTENAVA (bevacizumab gamma) approved in Europe and under FDA review in the US for wet AMD treatment.
What Outlook Therapeutics, Inc. does
Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing ophthalmic treatments for retinal diseases. The company's lead product is ONS-5010/LYTENAVA (bevacizumab gamma), an ophthalmic formulation of bevacizumab currently approved and commercially available in Germany and the United Kingdom for wet age-related macular degeneration (wet AMD), with a Biologics License Application under FDA review in the United States. The company is pursuing regulatory approval and commercialization in additional markets while managing manufacturing and distribution capabilities.
Themes: wet age-related macular degeneration (wet AMD), retinal disease treatment, ophthalmic biologics, FDA regulatory approval
Fundamentals
- Price$0.6233 as of 2026-08-26 close
- Market cap$75M as of 2026-08-26
- 1-year return-76.9% 2025-08-26 close $2.70 → 2026-08-26 close $0.6233
- P/En/a negative earnings
- Net margin-1507.0% as of 2026-08-27
- Gross margin+4.0% as of 2026-08-27
- ROE-415.5% as of 2026-08-27
- Debt / equity3.04 as of 2026-08-27
- Revenue growth (YoY)-22.9% as of 2026-08-27
- Beta0.62 as of 2026-08-27
- Last reported earnings2026-08-14 SEC EDGAR Form 8-K (Item 2.02)
How OTLK compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-27
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-27
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-27
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-27
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Outlook Therapeutics, Inc. looks technically
Outlook Therapeutics, Inc. (OTLK) is trading 31.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 30 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day low about 3 trading days ago. It is 81.6% below its highest point of the past year. Trading volume is unusually light — only about 27% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 31.5% below its 200-day average, the long-term trend line — a long-term downtrend | -31.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.24 | $1.24 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $0.9099 | $0.9099 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 1.3. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 30 trading days ago — a "golden cross", a bullish long-term signal | 30 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30) | 32.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($0.59 to $1.18) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 5.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.39 | $3.39 |
|---|---|---|
| From the 52-week high | it is 81.6% below its 52-week high (its highest price of the past year) | -81.6% |
| Above the 52-week low | it is 286.9% above its 52-week low (its lowest price of the past year) | +286.9% |
| Below the 52-week high | it is 81.6% below its highest point of the past year | 81.6% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $878.40 (set on 2016-09-01) | $878.40 |
| Given back of the 52-week move | over the past year its closes ranged ($0.1981 to $2.97), and it has recovered roughly a quarter of its fall from last year’s high — 15% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.91 to $2.00. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 15.3% |
| From the all-time high | it is 99.9% below its all-time high | -99.9% |
| Nearest price level | it is trading 26.0% above a support level at $0.4615 — a price it turned at twice since 2026-02-25, most recently on 2026-03-10. Since 2024-08-26 it has 2 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -26.0% |
| All-time low | its lowest closing price on record is $0.1611 (set on 2026-03-24) | $0.1611 |
| Above the all-time low | it is 286.9% above its all-time low | +286.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it) | 71st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1253 between its high and its low — about 20.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1253 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.49 and $1.23 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.49 – $0.86 – $1.23 |
| Typical daily range (% of price) | its price moves about 20.1% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 20.1% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges below its 200-day average price (31.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 27% of its 30-day average | 0.27× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 9.3% since the prior reading | -9.3% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a hammer | 6 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-26 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 5.1% below the previous close 8 sessions ago and has not traded back through the level it left behind at 0.89 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -5.1% |
| Gap filled | a 3.9% gap down opened on 2026-08-24 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 59.3 percentage points (the stock lost 55.6% while the market gained 3.7%) | -59.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 53.8 percentage points (the stock gained 55.8% while the market gained 2.1%) | +53.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 32.8 percentage points (the stock gained 43.9% while the market gained 11.1%) | +32.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 95.7 percentage points (the stock lost 76.9% while the market gained 18.7%) | -95.7% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 40% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 80.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -40.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 21% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $0.7882 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -20.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 17% below the average price paid since it last reported on 2026-08-12 (its 8-K), so the typical buyer over that stretch is under water. That average is $0.7472 — a volume-weighted average of daily closes over 11 sessions, not a true tick-by-tick VWAP. | -16.6% |
Price levels it has turned at before
OTLK last closed at $0.6233 on 2026-08-26. Since 2024-08-26 it has turned at 2 prices below its last close and 6 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.4615 | Support | 26.0% below the last close | turned there twice · 2026-02-25 to 2026-03-10 |
| $0.3915 | Support | 37.2% below the last close | turned there twice · 2026-02-18 to 2026-04-21 |
| $1.19 | Resistance | 90.9% above the last close | turned there twice · 2025-09-11 to 2025-09-29 |
| $1.55 | Resistance | 148.3% above the last close | turned there twice · 2025-07-01 to 2025-10-15 |
| $1.68 | Resistance | 169.5% above the last close | turned there twice · 2025-04-23 to 2025-12-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $1.30.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $1.07 and $1.30 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-12, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · Broke down to a new 20-day low · Analyst price target recently CUT · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$4.90 range $1.60 – $10.00; median $4.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OTLK
- Consensus EPS estimate-$0.06 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory risk: Inability to obtain and maintain FDA approval for ONS-5010/LYTENAVA in the United States and other markets","Commercialization risk: Failure to successfully commercialize LYTENAVA in the UK and EU markets and achieve market acceptance among physicians and patients","Funding risk: Insufficient cash resources and working capital to meet operational needs without additional financing"]
What changed in the latest 10-Q
AI-assisted comparison of OTLK's 10-Q filed 2026-05-15 against the prior one filed 2026-02-17.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-15) adds: 'Starting in June 2025, we launched directly into the initial markets of Germany and the UK. In 2026, we expanded into Austria and are planning for launches in other EU countries either directly or with a licensing partner.'
- Removed:
- Older filing (2026-02-17) states: 'In June 2025, we launched directly into the initial markets of Germany and the UK and are planning for launches in other EU countries either directly or with a licensing partner.' This language about planning for launches is modified in the newer filing to note that 2026 expansion into Austria already occurred.
- Reworded:
- Temporal update: Older filing uses present tense 'we launched directly into the initial markets' and future tense 'are planning for launches in other EU countries.' Newer filing uses past tense 'Starting in June 2025, we launched' and adds completed action 'In 2026, we expanded into Austria' before stating future 'are planning for launches in other EU countries.'
- Notes:
- The comparison is truncated at 'NORSE EIGHT) s' in the newer filing and 'NORSE EIGHT) seeking confirmation that, if successful, it would' in the older filing, suggesting the full section text was not provided for complete assessment.
- The substantive difference is the addition of Austria expansion information and temporal clarification in the newer filing, reflecting the passage of time between the two filing dates (approximately 3 months).
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
5 open-market purchases and 0 open-market sales by insiders in the last 90 days.
- Last 30 days4 buys ($3M) · 0 sells — 4 buying insiders
- Last 90 days5 buys ($3M) · 0 sells — 5 buying insiders
- Last 180 days10 buys ($8M) · 0 sells — 7 buying insiders
Cluster buying: 5 different insiders reported open-market purchases (SEC code P) of OTLK within a 30-day window between 2026-05-26 and 2026-06-02. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-14. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OTLK's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding OTLK as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,090,230
- Reported value $224,369
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 1 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
OTLK had 20,013,892 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
OTLK had 16.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.09 days to cover at the same settlement.
- Reported short interest (shares) 20,013,892
- Short interest (% of shares outstanding) 16.6%
- Prior settlement (shares) 11,240,969
- Reported change 78.04%
- Days to cover (reported) 1.09
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron Pharmaceuticals (REGN) - Eylea (aflibercept)
- Roche/Genentech - Avastin (bevacizumab)
- Novartis - Beovu (brolucizumab)
- Bausch Health - Retisert (fluocinolone acetonide)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OTLK vs…
OTLK shows up in…
Frequently asked questions
What does Outlook Therapeutics, Inc. (OTLK) do?
Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing ophthalmic treatments for retinal diseases. The company's lead product is ONS-5010/LYTENAVA (bevacizumab gamma), an ophthalmic formulation of bevacizumab currently approved and commercially available in Germany and the United Kingdom for wet age-related macular degeneration (wet AMD), with a Biologics License Application under FDA review in the United States.
What sector is Outlook Therapeutics, Inc. (OTLK) in?
Outlook Therapeutics, Inc. (OTLK) is classified in the Health Care sector. Its industry is Ophthalmic Biologics / Retinal Therapeutics. It trades on NASDAQ.
Who are Outlook Therapeutics, Inc.'s (OTLK) competitors?
Notable peers of Outlook Therapeutics, Inc. (OTLK) include Regeneron Pharmaceuticals (REGN) - Eylea (aflibercept), Roche/Genentech - Avastin (bevacizumab), Novartis - Beovu (brolucizumab) and Bausch Health - Retisert (fluocinolone acetonide). This peer set is informational only — not financial advice.
Is Outlook Therapeutics, Inc. (OTLK) overbought or oversold right now?
Outlook Therapeutics, Inc. (OTLK) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 33, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OTLK come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.